4.7 Article

ClonoMatch: a tool for identifying homologous immunoglobulin and T-cell receptor sequences in large databases

Journal

BIOINFORMATICS
Volume 36, Issue 24, Pages 5695-5697

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/bioinformatics/btaa1028

Keywords

-

Funding

  1. National Institutes of Health [U01 AI150739]
  2. Human Vaccines Project

Ask authors/readers for more resources

B-cell receptor (BCR) and T-cell receptor (TCR) repertoires are generated through somatic DNA rearrangements and are responsible for the molecular basis of antigen recognition in the immune system. Next-generation sequencing (NGS) of DNA and the falling cost of sequencing due to continued development of these technologies have made sequencing assays an affordable way to characterize the repertoire of adaptive immune receptors (sometimes termed the 'immunome'). Many new workflows have been developed to take advantage of NGS and have placed the resulting immunome datasets in the public domain. The scale of these NGS datasets has made it challenging to search through the Complementarity-determining region 3 (CDR3), which is responsible for imparting specific antibody-antigen interactions. Thus, there is an increasing demand for sequence analysis tools capable of searching through CDR3s from immunome data collections containing millions of sequences. To address this need, we created a software package called ClonoMatch that facilitates rapid searches in bulk immunome data for BCR or TCR sequences based on their CDR3 sequence or V3J clonotype.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Immunology

Human Antibodies for Viral Infections

James E. Crowe

Summary: Antibodies have been widely used for preventing and treating viral infections since the nineteenth century, and the development of potent human monoclonal antibodies has paved the way for unprecedented activities. Modifications that extend antibody half-life and the clinical development of broad and potent antibodies have the potential to make antibodies the principal tool in managing future viral epidemics. Furthermore, these antibodies are crucial for research and developing effective vaccines.

ANNUAL REVIEW OF IMMUNOLOGY (2022)

Editorial Material Microbiology

Even old foes can learn sweet new tricks

James E. Crowe, Robert H. Carnahan

Summary: The paper provides a comprehensive investigation into the molecular and functional basis of 17D vaccine responses, as well as the differences in antibody neutralization between the 17D and related African lineage strains and contemporary Central/South American strains.

CELL HOST & MICROBE (2022)

Article Multidisciplinary Sciences

Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity

Liya Hu, Wilhelm Salmen, Rong Chen, Yi Zhou, Frederick Neill, James E. Crowe, Robert L. Atmar, Mary K. Estes, B. V. Venkataram Prasad

Summary: This study reveals the structure and features of human norovirus GII.4 virus-like particles using X-ray crystallography and cryo-EM. It uncovers the adaptability and stability of the capsid protein VP1, as well as its potential antigen presentation mechanism, providing valuable insights for vaccine development.

NATURE COMMUNICATIONS (2022)

Article Cell Biology

Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening

Jennifer M. Pfaff-Kilgore, Edgar Davidson, Kathryn Kadash-Edmondson, Mayda Hernandez, Erin Rosenberg, Ross Chambers, Matteo Castelli, Nicola Clementi, Nicasio Mancini, Justin R. Bailey, James E. Crowe, Mansun Law, Benjamin J. Doranz

Summary: The E1 and E2 envelope proteins of hepatitis C virus (HCV) form a surprisingly fragile complex where even a single alanine mutation at 92% of positions disrupts its function. The identified amino-acid-level targets are highly conserved and functionally critical, providing potential opportunities for improved therapies and vaccines against hepatitis C.

CELL REPORTS (2022)

Article Microbiology

Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region

Clara T. Schoeder, Pavlo Gilchuk, Amandeep K. Sangha, Kaitlyn V. Ledwitch, Delphine C. Malherbe, Xuan Zhang, Elad Binshtein, Lauren E. Williamson, Cristina E. Martina, Jinhui Dong, Erica Armstrong, Rachel Sutton, Rachel Nargi, Jessica Rodriguez, Natalia Kuzmina, Brooke Fiala, Neil P. King, Alexander Bukreyev, James E. Crowe, Jens Meiler

Summary: This study presents the design and functional validation of an epitope-focused immunogen based on the HR2-MPER epitope of the ebolavirus. The results demonstrate the capabilities and challenges of computational epitope-focused vaccine design, and provide insights for the rational design of immunogens against ebolavirus.

PLOS PATHOGENS (2022)

Article Multidisciplinary Sciences

Structural mapping of antibody landscapes to human betacoronavirus spike proteins

Sandhya Bangaru, Aleksandar Antanasijevic, Nurgun Kose, Leigh M. Sewall, Abigail M. Jackson, Naveenchandra Suryadevara, Xiaoyan Zhan, Jonathan L. Torres, Jeffrey Copps, Alba Torrents de la Pena, James E. Crowe, Andrew B. Ward

Summary: This study investigated the antibody specificity against seasonal coronaviruses and SARS-CoV-2 in serum samples. The results showed that preexisting immunity contained antibodies specific to seasonal coronaviruses, while convalescent serum exhibited reactivity to all coronaviruses. Epitope mapping revealed differential targeting of epitopes by preexisting antibodies and convalescent serum antibodies.

SCIENCE ADVANCES (2022)

Article Multidisciplinary Sciences

Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals

Nina G. Bozhanova, Andrew Flyak, Benjamin P. Brown, Stormy E. Ruiz, Jordan Salas, Semi Rho, Robin G. Bombardi, Luke Myers, Cinque Soto, Justin R. Bailey, James E. Crowe, Pamela J. Bjorkman, Jens Meiler

Summary: Despite the success of antiviral treatment for HCV, the development of an HCV vaccine is still necessary to prevent reinfection, drug-resistant strains, and provide protection for individuals without access to antiviral therapy. This study identifies new antibodies with a specific structural motif that could inform future vaccine design.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies

Lauren E. Williamson, Abhishek Bandyopadhyay, Kevin Bailey, Devika Sirohi, Thomas Klose, Justin G. Julander, Richard J. Kuhn, James E. Crowe

Summary: This report presents cryo-electron microscopy reconstructions of three neutralizing human monoclonal antibodies against Eastern equine encephalitis virus (EEEV), and analyzes the factors contributing to the differences in their neutralization potencies. Structural and biophysical insights are provided, which can inform the design of candidate vaccines and therapeutic antibodies for all icosahedral viruses.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Cell Biology

A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans

Saravanan Raju, Lucas J. Adams, James T. Earnest, Kelly Warfield, Lo Vang, James E. Crowe Jr, Daved H. Fremont, Michael S. Diamond

Summary: By analyzing samples from a phase 2 clinical trial, researchers found that the PXVX0317 vaccine induced high levels of neutralizing antibodies and circulating antigen-specific B cells against chikungunya virus. Monoclonal antibodies generated from peripheral blood B cells of vaccinated individuals demonstrated potent neutralization of CHIKV and related arthritogenic alphaviruses. These findings highlight the inhibitory breadth and activity of the B cell response induced by the PXVX0317 vaccine against CHIKV and potentially other related alphaviruses.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Microbiology

Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody

Robert Stass, Taylor B. Engdahl, Nathaniel S. Chapman, Rachael M. Wolters, Laura S. Handal, Summer M. Diaz, James E. Crowe, Thomas A. Bowden

Summary: This study identifies a highly neutralizing human monoclonal antibody, SNV-42, that interferes with receptor recognition and fusion during hantavirus host-cell entry. Structural analysis reveals the mechanism by which SNV-42 binds to the Gn-Gc heterodimer lattice and inhibits viral infection, providing a blueprint for understanding the human neutralizing antibody response to hantavirus infection.

NATURE MICROBIOLOGY (2023)

Article Multidisciplinary Sciences

A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model

Cynthia M. McMillen, Nathaniel S. Chapman, Ryan M. Hoehl, Lauren B. Skvarca, Madeline M. Schwarz, Laura S. Handal, James E. Crowe Jr, Amy L. Hartman

Summary: The authors demonstrate in rodent models that a neutralizing monoclonal antibody can prevent vertical transmission of RVFV both before and after infection. RVFV is an emerging mosquito-transmitted virus that circulates in livestock and humans in Africa and the Middle East. The antibody reduces viral replication and provides protection against RVFV infection and vertical transmission in both dams and offspring.

NATURE COMMUNICATIONS (2023)

Article Medicine, Research & Experimental

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency

Nicole Frumento, Alexis Figueroa, Tingchang Wang, Muhammad N. Zahid, Shuyi Wang, Guido Massaccesi, Georgia Stavrakis, James E. Crowe, Andrew Flyak, Hongkai Ji, Stuart C. Ray, George M. Shaw, Andrea L. Cox, Justin R. Bailey

Summary: This study investigated the development of broadly neutralizing antibodies (bNAbs) in HCV-infected individuals, including those with persistent infection or spontaneous clearance of multiple reinfections. The findings showed that the breadth and potency of the antibody response increased with exposure to genetically distinct infections and longer duration of viremia. Importantly, repeated exposure to antigenically related, antibody-sensitive envelope proteins was associated with potent bNAb induction. These results suggest that a prime-boost vaccine strategy with genetically distinct, antibody-sensitive viruses could be a promising approach to inducing potent bNAbs in humans.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Medicine, Research & Experimental

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques

Ronald R. Cobb, Joseph Nkolola, Pavlo Gilchuk, Abishek Chandrashekar, Jingyou Yu, Robert House, Christopher G. Earnhart, Nicole M. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen, Laura A. VanBlargan, Manuel Hechenblaickner, Brian Hoppe, Laura Collins, Milan T. Tomic, Genevieve H. Nonet, Kyal Hackett, James C. Slaughter, Mark G. Lewis, Hanne Andersen, Anthony Cook, Michael S. Diamond, Robert H. Carnahan, Dan H. Barouch, James E. Crowe

Summary: This study demonstrates that neutralizing antibodies with extended half-life and lacking Fc-mediated effector functions are highly effective for pre-exposure prophylaxis of SARS-CoV-2 infection in NHPs, supporting the clinical development of ADM03820 for COVID-19 prevention.
Article Medicine, Research & Experimental

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

Naveenchandra Suryadevara, Andrea R. Shiakolas, Laura A. VanBlargan, Elad Binshtein, Rita E. Chen, James Brett Case, Kevin J. Kramer, Erica C. Armstrong, Luke Myers, Andrew Trivette, Christopher Gainza, Rachel S. Nargi, Christopher N. Selverian, Edgar Davidson, Benjamin J. Doranz, Summer M. Diaz, Laura S. Handal, Robert H. Carnahan, Michael S. Diamond, Ivelin S. Georgiev, James E. Crowe

Summary: This study identifies a rare human antibody, COV23434, that disrupts the integrity of the SARS-CoV-2 S protein and possesses a distinct class of functional activity. The findings suggest that the trimer interface region of the S protein may be a vulnerable site for the virus.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available